PIOSSOBIA DAJ3.

4 Approved for use through 2013/1000,000 MB 658 4031

U.S. Peinies at Transmiss Origin, U.S. DEPARTIEST OF COMMERCE
Under the Pepervoick Reduction Act of 1995, no persons are required to respond to a collection of information review to continue a visit OFM control meriter.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		1051/16/	
	Filing Date		2005-01-24	
	First Named Inventor	Shiny	ra Kawachi	
	Art Unit		1745	
	Examiner Name	N/A		
	Attorney Docket Number SHM-15820			

					U.S.I	PATENTS			Remove	
Examiner Cite Initial* Patent Number Kind Code1 Issue D			Date	Name of Patentee or Applicant			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wisl	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Cite Publication Number Kind Code1		Publica Date			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1									
If you wis	h to a	dd additional U.S. Publi								
				FOREK	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or v	Pages,Columns,Line where Relevant Passages or Releva Figures Appear	T.
	1	09-237633	JP			1997-09-09	Aisin Takaoka Ltd		English abstract ncluded	
	2	10-074530	JP			1998-03-17	Aisin Takaoka Ltd		English abstract ncluded	Г
	3	11-129396	JP			1999-05-18	Aisin Takaoka Ltd		English abstract notuded	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10517167	
iling Date		2005-01-24	
irst Named Inventor	Shiny	Shinya Kawachi	
urt Unit		1745	
xaminer Name	N/A		
ttorney Docket Number		SHM-15820	

	4	2002-075396	JP		2002-03-15	Toyota Motor Corp	English abstract included		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Тб	
	1								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

See for Codes of USPTO Platent Documents at year, USPTO, DOLL or MEPP 071.04. * Enter office an all issued for a document, by the ho-letter code (WIPO Standard ST3, 3. * Projection Standard ST3, 4. * Projection ST3, 4.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10517167
Filing Date		2005-01-24
First Named Inventor	Shiny	a Kawachi
Art Unit		1745
Examiner Name N/A		
Attorney Docket Number		SHM-15820

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(40).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

David E Snaw

▼ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

34732

Signature //David E. Spaw/ Date (YYYY-MM-DD) 2007-03-22	

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleater and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.